Pathological response measured using virtual microscopic slides for gastric cancer patients who underwent neoadjuvant chemotherapy

Table 1 Clinicopathological characteristics of the patients

Background	n (%)	Background	n (%)
Age	Median 64	M-classification
	Range 39–77
< 65 yr	28 (51.9)	0	51 (94.4)
≥ 65 yr	26 (48.1)	1	3 (5.6)
Gender		Tumor histology
Male	40 (74.1)	Differentiated	26 (48.1)
Female	14 (25.9)	Undifferentiated	28 (51.9)
ECOG PS		Reason for NAC
0	46 (85.2)	Clinical SE or T4b	14 (25.9)
1	8 (14.8)	Extended LN	24 (44.4)
Tumor type		Large type 3	5 (9.3)
Non-type 4	44 (81.5)	Type 4	4 (7.4)
Type 4	10 (18.5)	Others	7 (13.0)
Primary site		HER2 overexpression
Stomach	51 (94.4)	Negative or unknown	48 (88.9)
Esophagogastric junction	3 (5.6)	Positive	6 (11.1)
T-classification		NAC regimen
1	1 (1.9)	SP or SOX (+ trastuzumab)	49 (90.7)
2	2 (3.7)	DCS	5 (9.3)
3	13 (24.1)	Adjuvant treatment
4	38 (70.4)	S-1	52 (96.3)
N-classification		Others or no treatment	2 (3.7)
0	6 (11.1)	Participant of clinical trials
1	10 (18.5)	Yes	17 (31.5)
2	22 (40.7)	No	37 (68.5)
3	15 (27.8)
Not evaluable	1 (1.9)

NAC: Neoadjuvant chemotherapy; LN: Lymph node; SP: S-1 + cisplatin; SOX: S-1 + oxaliplatin; DCS: Docetaxel + cisplatin + S-1; ECOG PS: Eastern cooperative oncology group performance status.